Welltower stands as the largest healthcare real estate investment trust (REIT) globally, with a focus on senior housing and wellness properties spanning the United States, Canada, and the United Kingdom. Its quarterly updates serve as a useful indicator for the broader "silver economy," supported by demographic trends from an aging population and constrained new supply in senior housing. The third-quarter results are particularly relevant because they show how effectively the company is translating occupancy gains and pricing power into higher normalized funds from operations (FFO), a key REIT metric that adjusts for real estate depreciation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors keep an eye on same-store net operating income (NOI) trends and any updates to guidance for clues about demand strength and margin stability going forward.
In the third quarter of 2026, Welltower posted normalized FFO of $1.67 per diluted share. That figure marked a 24.6% increase from $1.34 in the same period a year earlier and came in slightly above analyst forecasts. Revenue climbed 15.8% to $3.72 billion, which topped the consensus estimate of about $3.66 billion and compared with $2.69 billion in the prior-year quarter.
GAAP net income attributable to common stockholders landed at $0.54 per diluted share, missing the consensus mark of roughly $0.65. The gap largely stems from real estate depreciation and other non-cash items that FFO metrics are intended to exclude. On the operational side, the Seniors Housing Operating (SHO) portfolio performed well, with same-store NOI rising 21.0% and organic revenue growth of 9.1%. These gains were driven by a 320-basis-point increase in average occupancy and a 5.3% rise in revenue per occupied room (RevPOR).
Shares of Welltower edged modestly lower in after-hours trading after the release, declining roughly 0.5% to 1% even though FFO exceeded expectations and guidance was raised. The tempered response appears tied to attention on the net income shortfall versus consensus, along with the stock’s valuation following an extended advance. Sentiment before the report had been constructive, backed by four straight quarters of normalized FFO beats and sustained demand from demographic factors. The latest results largely supported that narrative, yet the bottom-line miss prompted some traders to adopt a wait-and-see approach in the short term.
Management raised its full-year 2026 outlook, now projecting normalized FFO of $6.47 to $6.53 per share (previously $6.36 to $6.44) and net income attributable to common stockholders of $3.31 to $3.37 per share (previously $3.11 to $3.19). The updated ranges point to continued confidence that occupancy and pricing trends in senior housing will hold.
Several areas deserve attention in upcoming quarters. One is whether same-store NOI growth can remain in double digits and whether occupancy and RevPOR improvements extend across more of the portfolio. Capital deployment is another focus: the company completed $4.1 billion of pro rata gross investments in the quarter, including $2.7 billion across 43 senior-housing properties, so the pipeline will influence future earnings. Balance-sheet metrics also matter, with net debt to adjusted EBITDA at 3.02x and about $9.5 billion in available liquidity. Finally, interest-rate conditions, acquisition costs, and the recently declared $0.85 quarterly dividend will shape the pace of external growth and payout discipline.
When analyzing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter REITs by fundamentals, technical patterns, and performance metrics. It helps surface comparable names and spot broader sector trends without manual effort. The tool has become a regular part of my routine for evaluating opportunities in healthcare real estate and other industries.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WELL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 22 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 52%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 62 cases where WELL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 44%.
The Momentum Indicator moved below the 0 level on November 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WELL as a result. In 34 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 44%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WELL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.
WELL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for WELL entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
WELL moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for WELL crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.
Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where WELL advanced for three days, in 229 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 32 (best 1 - 100 worst), indicating outstanding price growth. WELL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.804) is normal, around the industry mean (3.134). WELL has a moderately high P/E Ratio (110.365) as compared to the industry average of (30.791). WELL's Projected Growth (PEG Ratio) (3.660) is slightly higher than the industry average of (1.649). Dividend Yield (0.014) settles around the average of (0.050) among similar stocks. WELL's P/S Ratio (13.316) is slightly higher than the industry average of (6.013).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a real estate investment trust
Industry PublishingBooksMagazines